Bio-Path (BPTH) to Release Earnings on Friday

Bio-Path (NASDAQ:BPTH) will likely be releasing its resultson Friday, March 20th. Analysts expect Bio-Path to post earnings of ($0.40) per share for the quarter.

Bio-Path Stock Down 5.1%

Bio-Path stock opened at $0.07 on Friday. The business has a 50 day moving average price of $0.06 and a two-hundred day moving average price of $0.07. Bio-Path has a 12 month low of $0.05 and a 12 month high of $0.23. The stock has a market cap of $610,966.80, a price-to-earnings ratio of -0.06 and a beta of -0.24.

Bio-Path Company Profile

Bio-Path Holdings, Inc (NASDAQ:BPTH) is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for cancer and other serious diseases. The company’s platform centers on its proprietary Liposomal DNA Antisense Technology (LDAT), which leverages liposome-based delivery to transport antisense DNA molecules directly into targeted cells. By silencing specific messenger RNAs (mRNAs) associated with disease, Bio-Path aims to modulate pathways that drive tumor growth and survival.

The company’s lead investigational therapy, prexigebersen (BP1001), is designed to inhibit Grb2 mRNA, a critical adaptor protein involved in multiple oncogenic signaling pathways.